Description

Clinical Evidence

• Sermorelin has been studied for its potential to reverse age-related GH decline and support endocrine balance in GH-deficient individuals.
• Clinical data show that Sermorelin may improve IGF-1 levels, increase lean body mass, and reduce fat mass with a safer endocrine profile than exogenous GH.
• In pediatric applications, Sermorelin has been investigated for growth hormone deficiency, offering a dynamic alternative to direct GH injection.
Note: Sermorelin is often used in combination with GHRPs (like GHRP-2 or Ipamorelin) in research settings for synergistic GH release.

Potential Side Effects

Most side effects are mild, dose-dependent, and transient:
• Redness or irritation at the injection site
• Headache or flushing
• Temporary drowsiness or dizziness
• Mild water retention
• Rare: tingling or numbness in extremities
As a GH secretagogue, Sermorelin avoids the risks associated with synthetic GH overdose but should still be used with proper monitoring in research.

Disclaimer

This product is intended for laboratory research use only and is not approved for human or veterinary consumption. All clinical references are for informational purposes only. It should be handled by qualified professionals in a secure and controlled environment.